Jones Trading raises Femasys shares PT to $10, cites ‘topline’ study results By Investing.com

On Wednesday, Jones Trading increased its price target for Femasys Inc. (NASDAQ:) to $10.00, up from the previous target of $7.00, while reaffirming a Buy rating on the stock. This adjustment follows the announcement of promising results from the FemaSeed infertility study.

Femasys recently reported outcomes from the FemaSeed study, which indicated a significant improvement in pregnancy rates. The study showed a pregnancy rate of 16% per cycle, a substantial increase compared to the 6.7% rate observed with intrauterine insemination (IUI).

The study specifically analyzed the efficacy of FemaSeed in cases of male-factor infertility, characterized by a total motile sperm count between 1 million and 20 million. An impressive 24% of participants with male-factor infertility achieved pregnancy following the FemaSeed treatment.

The FemaSeed product has already received clearance from the FDA, and the latest study results are expected to solidify its position as a viable alternative to in vitro fertilization (IVF). This is particularly noteworthy in light of the recent Alabama Supreme Court decision on embryos produced during IVF treatments.

Jones Trading highlights that Femasys is well-positioned financially to support the commercial launch of FemaSeed, with sufficient capital to extend into the second half of 2025. The positive data from the FemaSeed study leads to the anticipation of increased market penetration, prompting the firm to raise its price target for Femasys shares.

InvestingPro Insights

Following the optimistic outlook from Jones Trading on Femasys Inc. (NASDAQ:FEMY), InvestingPro offers additional insights that could be of interest to investors. With a market capitalization of 43.3 million USD, Femasys stands as a company of note in the biotechnology space. Notably, the stock has experienced a significant return over the last week, with a 10.5% price total return, and an even more remarkable six-month price total return of 520.54%. This could reflect the market’s positive reaction to recent developments, including the promising results from the FemaSeed infertility study.

Despite the company’s impressive returns, InvestingPro highlights some concerns: Femasys is not currently profitable, with a negative P/E ratio of -3.4 for the last twelve months as of Q3 2023. Additionally, the company has been quickly burning through cash, which could pose risks for long-term sustainability. Nevertheless, Femasys holds more cash than debt on its balance sheet, providing a cushion for its aggressive growth strategies.

For investors looking for deeper analysis, InvestingPro has 12 additional InvestingPro Tips that could help in evaluating the potential of Femasys Inc. Remember to use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes these valuable tips. With the next earnings date approaching on March 21, 2024, these insights could be crucial for making informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.